WallStreetZenWallStreetZen

NASDAQ: MURA
Mural Oncology PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their MURA stock forecasts and price targets.

Forecast return on equity

Is MURA forecast to generate an efficient return?

Company
-66.9%
Industry
94.09%
Market
-61.86%
MURA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MURA forecast to generate an efficient return on assets?

Company
-44.92%
Industry
35.92%
MURA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MURA earnings per share forecast

What is MURA's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$5.66
Avg 2 year Forecast
-$0.39
Avg 3 year Forecast
-$0.12

MURA revenue forecast

What is MURA's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$5.6M
Avg 2 year Forecast
$17.4M
Avg 3 year Forecast
$44.0M

MURA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MURA$2.10N/AN/A
VRCA$3.91N/AN/A
NRXS$3.79$7.00+84.70%Buy
NERV$5.38N/AN/A
IGC$0.38$4.50+1,087.34%Buy
View Top Biotech Stocks

Mural Oncology Stock Forecast FAQ

What is MURA's earnings growth forecast for 2025-2027?

(NASDAQ: MURA) Mural Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 4.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.91%.

Mural Oncology's earnings in 2025 is -$147,152,000.On average, 1 Wall Street analyst forecast MURA's earnings for 2025 to be -$98,055,872, with the lowest MURA earnings forecast at -$98,055,872, and the highest MURA earnings forecast at -$98,055,872. On average, 1 Wall Street analyst forecast MURA's earnings for 2026 to be -$6,756,500, with the lowest MURA earnings forecast at -$6,756,500, and the highest MURA earnings forecast at -$6,756,500.

In 2027, MURA is forecast to generate -$2,078,923 in earnings, with the lowest earnings forecast at -$2,078,923 and the highest earnings forecast at -$2,078,923.

If you're new to stock investing, here's how to buy Mural Oncology stock.

What is MURA's revenue growth forecast for 2026-2028?

(NASDAQ: MURA) Mural Oncology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.15%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.71%.

Mural Oncology's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast MURA's revenue for 2026 to be $97,709,385, with the lowest MURA revenue forecast at $97,709,385, and the highest MURA revenue forecast at $97,709,385. On average, 1 Wall Street analysts forecast MURA's revenue for 2027 to be $301,980,902, with the lowest MURA revenue forecast at $301,980,902, and the highest MURA revenue forecast at $301,980,902.

In 2028, MURA is forecast to generate $762,271,796 in revenue, with the lowest revenue forecast at $762,271,796 and the highest revenue forecast at $762,271,796.

What is MURA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MURA) forecast ROA is -44.92%, which is lower than the forecast US Biotechnology industry average of 35.92%.

What is MURA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MURA) Mural Oncology's current Earnings Per Share (EPS) is -$8.59. On average, analysts forecast that MURA's EPS will be -$5.66 for 2025, with the lowest EPS forecast at -$5.66, and the highest EPS forecast at -$5.66. On average, analysts forecast that MURA's EPS will be -$0.39 for 2026, with the lowest EPS forecast at -$0.39, and the highest EPS forecast at -$0.39. In 2027, MURA's EPS is forecast to hit -$0.12 (min: -$0.12, max: -$0.12).

What is MURA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MURA) forecast ROE is -66.9%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.